ESMO21: Results of first randomized trial, FIRSTMAPPP, for rare neuroendocrine tumor

A team of researchers presented the first randomized study for a rare neuroendocrine tumor, entitled the First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (FIRSTMAPPP), demonstrating that sunitinib could prolong progression-free survival (PFS) by more than 5 months. Malignant pheochromocytoma paraganglioma (MPP) maintains an incidence of less than one in a million individuals every year. FIRSTMAPPP enrolled 78 patients with progressive MPP from 15 centers in four countries, all in Europe. Participants, whose average age was 53 and of which 59% were male, were randomly allocated sunitinib or a placebo therapeutic. At 12 months of treatment, PFS was...